"3·15" Named Source Gene: Local Government "Strongly Recommends," Actual Controller is Director of A-stock Company

What impact does the identity of A-share board members have on the event?

At the “3.15” Gala in 2026, exosome chaos was called out. Financial News noticed that the company named was Yuanchuang Gene Technology Co., Ltd., which holds titles such as high-tech enterprise and specialized and innovative small and medium-sized enterprise, and may also have connections with A-share companies.

According to the Gala report, the bioactive substance “exosome,” which is still under debate, has been perceived as a business opportunity by some market players. To date, China has not approved any products containing exosomes for market release, but some companies still engage in false advertising. They claim their exosome products can beautify and anti-age, and some even exaggerate that they can treat various diseases.

One company located in a city in Central China, Yuanchuang Gene Technology Co., Ltd., was implicated. The company’s General Manager Han explained that their exosome products are divided into several grades, with the lowest grade sold to the medical aesthetics industry, which has the least effect. “From a technical difficulty level, medical aesthetics is the lowest tier, followed by sub-health care and chronic diseases, and the highest level is for tumor treatment.”

Han also stated that injecting their “exosome” products carries significant regulatory risks. These products have not been approved by the government, so they do not administer exosome injections to patients through their company.

Qichacha data shows that the only company with a similar name is Zhengzhou Yuanchuang Gene Technology Co., Ltd. (hereinafter referred to as “Yuanchuang Gene”). Yuanchuang Gene was established in 2016 with a paid-in capital of 22.2 million yuan, registered in Zhengzhou’s Airport Economy Zone, and holds titles such as high-tech enterprise, specialized and innovative small and medium-sized enterprise, and science and technology-based SME. Financial News accessed Yuanchuang Gene’s official website via Qichacha, which displayed pages related to product sales and distribution information.

Qichacha data shows that individual Zhao Hui holds over 60% of Yuanchuang Gene’s shares, making him the actual controller. Besides Yuanchuang Gene, Zhao Hui is also associated with nearly 10 other companies. Notably, he is a non-independent director of Berry Genomics (000710.SZ).

Source: Qichacha

According to Berry Genomics, Zhao Hui was born in March 1975, is a Chinese national, has no permanent residence abroad, and holds a Ph.D. from the Beijing Institute of Genomics, Chinese Academy of Sciences. He has served as a postdoctoral researcher at Columbia University College of Physicians and Surgeons, a deputy researcher at Columbia University Cancer Center in the U.S., and is currently the chairman and chief scientist of Zhengzhou Yuanchuang Gene Technology Co., Ltd.

Public information indicates that Yuanchuang Gene claims to have leading capabilities in cell therapy and related fields. According to the official account of the Zhengzhou Airport Economy Zone Management Committee, Yuanchuang Gene was once highlighted as a key development achievement of the Zhengzhou Airport Economy Zone.

Source: Henan Zhengzhou Airport Release